Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma is a PHASE2 clinical asset sponsored by Zhejiang University in Multiple Myeloma, New Diagnosis Tumor. SEO and diligence focus: BCMA CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Multiple Myeloma
Modality: cell therapy
Target: BCMA CAR-T cells
Sponsor: Zhejiang University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCMA CAR-T cells
View original source fields
Condition raw: Multiple Myeloma, New Diagnosis Tumor
Condition normalized: Multiple Myeloma, New Diagnosis Tumor
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: BCMA CAR-T cells
Target normalized: BCMA CAR-T cells